GlassScriptPhysician profile
David Claude Snyder
NPI 1053395145
$3,701.40
in general payments reported to CMS, 2019-2025
39 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $230 · 2021: $226 · 2022: $814 · 2023: $286 · 2024: $703 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $586.34 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.28 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $288.07 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Electromed, INC. | $242.99 | 2021-2025 | Smartvest |
| Grifols USA, LLC | $240.70 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $167.66 | 2019-2024 | Tyvaso |
| Inspire Medical Systems, INC. | $157.25 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $145.06 | 2019-2024 | |
| Mylan Specialty L.P. | $134.29 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $127.32 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $113.84 | 2022-2025 | Tezspire |
| Baxter Healthcare | $111.30 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $106.12 | 2021-2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $106.05 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $85.71 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.